Envveno Medical Corporation Financials

NVNO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Envveno Medical Corporation (NVNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

N/A

EBITDA

-$23.6M

YoY+4.4%

Envveno Medical Corporation's EBITDA was -$23.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.4% from the prior year.

Free Cash Flow

-$16.9M

YoY-7.3%

Envveno Medical Corporation generated -$16.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 7.3% from the prior year.

Net Income

-$21.8M

YoY+11.6%

Envveno Medical Corporation reported -$21.8M in net income in fiscal year 2024. This represents an increase of 11.6% from the prior year.

EPS (Diluted)

$-1.27

YoY+42.3%

Envveno Medical Corporation earned $-1.27 per diluted share (EPS) in fiscal year 2024. This represents an increase of 42.3% from the prior year.

Cash & Debt

$1.8M

YoY-61.5%

5Y CAGR-8.5%

Envveno Medical Corporation held $1.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+85.1%

5Y CAGR+8.4%

Envveno Medical Corporation had 18M shares outstanding in fiscal year 2024. This represents an increase of 85.1% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$12.2M

YoY+23.6%

5Y CAGR+58.1%

Envveno Medical Corporation invested $12.2M in research and development in fiscal year 2024. This represents an increase of 23.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$37K

YoY-67.8%

5Y CAGR+24.4%

Envveno Medical Corporation invested $37K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.8% from the prior year.

NVNO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	$31K-83.3%	$187K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$187K
R&D Expenses	$12.2M+23.6%	$9.9M+73.1%	$5.7M+34.7%	$4.3M+92.7%	$2.2M+78.1%	$1.2M
SG&A Expenses	$11.6M-22.9%	$15.0M+34.5%	$11.2M+128.7%	$4.9M-0.6%	$4.9M-24.2%	$6.5M
Operating Income	-$23.8M+4.4%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M-19.0%	-$7.7M+2.3%	-$7.9M
Interest Expense	N/A	$161K+747.4%	$19K+408.2%	$4K+107.5%	-$50K-116.7%	$298K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$21.8M+11.6%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M-19.8%	-$7.6M+41.5%	-$13.0M
EPS (Diluted)	$-1.27+42.3%	$-2.20	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M-10.6%	$2.9M+13.1%	$2.6M	N/A	$2.8M-33.6%	$4.2M+17.2%	$3.6M	N/A
SG&A Expenses	$2.3M-44.7%	$4.2M+73.5%	$2.4M	N/A	$2.6M-1.9%	$2.6M-18.8%	$3.2M	N/A
Operating Income	-$4.9M+30.7%	-$7.0M-42.3%	-$5.0M	N/A	-$5.3M+21.5%	-$6.8M-0.3%	-$6.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+32.2%	-$6.7M-48.7%	-$4.5M	N/A	-$5.0M+22.8%	-$6.5M-1.3%	-$6.4M	N/A
EPS (Diluted)	$-0.23+30.3%	$-0.33-50.0%	$-0.22	N/A	$-0.45+22.4%	$-0.58-1.8%	$-0.57	N/A

NVNO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$45.0M+7.9%	$41.7M-27.8%	$57.7M+447.5%	$10.5M+206.8%	$3.4M-3.5%	$3.6M
Current Assets	$43.7M+10.9%	$39.4M-28.4%	$55.0M+475.2%	$9.6M+572.0%	$1.4M-49.8%	$2.8M
Cash & Equivalents	$1.8M-61.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M+614.1%	$1.3M-52.3%	$2.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$32K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M-4.7%	$2.9M-11.0%	$3.3M-4.2%	$3.4M+40.7%	$2.4M+60.5%	$1.5M
Current Liabilities	$2.1M+36.9%	$1.5M-3.2%	$1.6M-50.4%	$3.2M+69.8%	$1.9M+23.2%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.2M+8.9%	$38.7M-28.8%	$54.4M+666.5%	$7.1M+617.0%	$990K-51.4%	$2.0M
Retained Earnings	-$151.9M-42.6%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M-16.3%	-$56.2M-15.7%	-$48.6M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$32.4M-11.6%	$36.6M-9.9%	$40.6M-16.6%	$48.6M+73.1%	$28.1M-12.4%	$32.1M-12.4%	$36.6M-12.1%	$41.7M
Current Assets	$31.5M-11.5%	$35.6M-9.8%	$39.5M-15.9%	$46.9M+79.0%	$26.2M-12.9%	$30.1M-12.8%	$34.5M-12.5%	$39.4M
Cash & Equivalents	$1.5M-24.5%	$2.0M-30.4%	$2.9M-18.9%	$3.6M-26.8%	$4.9M+4.9%	$4.7M+107.4%	$2.3M-50.1%	$4.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M-17.5%	$3.5M+55.1%	$2.3M-6.8%	$2.4M-23.4%	$3.2M-2.9%	$3.3M+31.8%	$2.5M-15.3%	$2.9M
Current Liabilities	$2.4M-20.4%	$3.0M+81.5%	$1.7M+21.2%	$1.4M-32.5%	$2.0M-1.7%	$2.1M+77.1%	$1.2M-23.7%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.4M-10.9%	$33.1M-13.7%	$38.3M-17.1%	$46.2M+85.4%	$24.9M-13.5%	$28.8M-15.6%	$34.1M-11.9%	$38.7M
Retained Earnings	-$167.6M-2.8%	-$163.1M-4.3%	-$156.4M-20.2%	-$130.0M-4.5%	-$124.4M-4.2%	-$119.4M-5.7%	-$112.9M-6.0%	-$106.5M

NVNO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$16.8M-7.8%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M-30.2%	-$5.9M+7.2%	-$6.4M
Capital Expenditures	$37K-67.8%	$115K-68.8%	$368K+104.1%	$180K-50.5%	$364K+2829.4%	$12K
Free Cash Flow	-$16.9M-7.3%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M-25.5%	-$6.3M+1.7%	-$6.4M
Investing Cash Flow	$1.3M+103.9%	-$34.6M-9289.7%	-$368K-104.1%	-$180K+50.5%	-$364K-2829.4%	-$12K
Financing Cash Flow	$13.6M	N/A	$57.6M+282.1%	$15.1M+167.4%	$5.6M-37.6%	$9.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	N/A	N/A	-$4.0M	N/A	N/A	N/A	-$5.1M	N/A
Capital Expenditures	N/A	N/A	$10K	N/A	N/A	N/A	$5K	N/A
Free Cash Flow	N/A	N/A	-$3.6M	N/A	N/A	N/A	-$5.1M	N/A
Investing Cash Flow	N/A	N/A	$5.2M	N/A	N/A	N/A	$2.8M	N/A
Financing Cash Flow	N/A	N/A	$46K	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NVNO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	100.0%
Operating Margin	N/A	N/A	N/A	N/A	-24566.5%-20356.0pp	-4210.5%
Net Margin	N/A	N/A	N/A	N/A	-24406.7%-17415.3pp	-6991.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-48.5%+10.7pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%+135.4pp	-222.0%+144.4pp	-366.4%
Current Ratio	20.88-4.9	25.78-9.1	34.84+31.8	3.00+2.2	0.76-1.1	1.86
Debt-to-Equity	0.070.0	0.08+0.0	0.06-0.4	0.48-2.0	2.47+1.7	0.75
FCF Margin	N/A	N/A	N/A	N/A	-20037.4%-16623.8pp	-3413.7%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-14.0%+4.3pp	-18.3%-7.2pp	-11.1%	N/A	-17.8%+2.4pp	-20.2%-2.7pp	-17.5%	N/A
Current Ratio	13.12+1.3	11.81-12.0	23.77-10.5	34.23+21.3	12.91-1.7	14.57-15.0	29.58+3.8	25.78
Debt-to-Equity	0.100.0	0.11+0.0	0.060.0	0.05-0.1	0.13+0.0	0.11+0.0	0.070.0	0.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Financial Health Signals

Piotroski F-Score Weak

2/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Low Quality

0.77x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Similar Companies

Intelligent Bio Solutions Inc INBS

$6.0M

Nexalin Tech NXL

$8.3M

Ainos Inc AIMD

$11.0M

ALLURION TECHNOLOGIES INC ALUR

$13.0M

Beyond Air Inc XAIR

$10.7M

Frequently Asked Questions

Is Envveno Medical Corporation profitable?

No, Envveno Medical Corporation (NVNO) reported a net income of -$21.8M in fiscal year 2024.

What is Envveno Medical Corporation's earnings per share (EPS)?

Envveno Medical Corporation (NVNO) reported diluted earnings per share of $-1.27 for fiscal year 2024. This represents a 42.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Envveno Medical Corporation's EBITDA?

Envveno Medical Corporation (NVNO) had EBITDA of -$23.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Envveno Medical Corporation's free cash flow?

Envveno Medical Corporation (NVNO) generated -$16.9M in free cash flow during fiscal year 2024. This represents a -7.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Envveno Medical Corporation's operating cash flow?

Envveno Medical Corporation (NVNO) generated -$16.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Envveno Medical Corporation's total assets?

Envveno Medical Corporation (NVNO) had $45.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Envveno Medical Corporation's capital expenditures?

Envveno Medical Corporation (NVNO) invested $37K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Envveno Medical Corporation spend on research and development?

Envveno Medical Corporation (NVNO) invested $12.2M in research and development during fiscal year 2024.

How many shares does Envveno Medical Corporation have outstanding?

Envveno Medical Corporation (NVNO) had 18M shares outstanding as of fiscal year 2024.

What is Envveno Medical Corporation's current ratio?

Envveno Medical Corporation (NVNO) had a current ratio of 20.88 as of fiscal year 2024, which is generally considered healthy.

What is Envveno Medical Corporation's debt-to-equity ratio?

Envveno Medical Corporation (NVNO) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Envveno Medical Corporation's return on assets (ROA)?

Envveno Medical Corporation (NVNO) had a return on assets of -48.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Envveno Medical Corporation's cash runway?

Based on fiscal year 2024 data, Envveno Medical Corporation (NVNO) had $1.8M in cash against an annual operating cash burn of $16.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Envveno Medical Corporation's Piotroski F-Score?

Envveno Medical Corporation (NVNO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Envveno Medical Corporation's earnings high quality?

Envveno Medical Corporation (NVNO) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.